Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Is Rallying Again Today

By Zhiyuan Sun – Aug 5, 2021 at 1:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Finally, some good news for this emerging biotech.

What happened

Shares of coronavirus vaccine developer Novavax (NVAX -2.88%) are up 6.7% to $238.56 apiece as of 10:30 a.m. EDT. The stock has gained over 30% in the past five trading days.

On Aug. 4, Novavax announced the European Commission would purchase 100 million doses of its coronavirus vaccine candidate NVX-CoV2373, with an additional option to purchase 100 million doses by the end of 2023. In clinical studies, the vaccine candidate demonstrated 89.7% to 96.4% overall efficacy in immunization, depending on the strain of the coronavirus. 

A healthcare worker puts a bandage on a child's arm.

Image source: Getty Images.

So what

The company desperately needed the good news after a series of corporate and supply chain delays damaged the vaccine candidate's reputation. Last year, the U.S. government gave Novavax a $1.6 billion grant in exchange for 100 million doses of NVX-CoV2373. Delivery is still pending. The U.K. government also ordered 60 million doses of the vaccine candidate in March, but they never arrived. The vaccine candidate is still pending regulatory clearance, such as from the European Medical Agency and the U.S. Food and Drug Administration.

Now what

It seems Novavax's supply chain issues are about to end. The company's manufacturing partner, the Serum Institute of India, commenced production of NVX-CoV2373 in late June. With its capacity, Novavax will be on track to produce 150 million doses of NVX-CoV2373 by the end of the year. The company still has a relatively small market cap ($16.58 billion) compared to its coronavirus vaccine peers like Moderna and BioNTech, so there's a lot of potential for the biotech to grow.

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.54 (-2.88%) $0.49
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.